Personalis Files Merger Proxy for Tempus AI Takeover, Vote Set Nov. 30

What happened

Personalis, Inc., a Fremont, California-based cancer genomics company that runs a medical laboratory business, filed a definitive proxy statement on October 21, 2026, asking stockholders to approve its acquisition by Tempus AI, Inc.

The filing sets a virtual special stockholder meeting for November 30, 2026 at 9:00 a.m. Pacific Time. Stockholders of record as of the close of business on October 15, 2026 are entitled to vote. Personalis shares closed at $15.90 on the day the proxy was filed, down 0.25% from the prior close of $15.94.

Under the merger agreement, dated July 20, 2026, each Personalis share will convert into the right to receive Tempus Class A common stock at an exchange ratio of 0.3356 if Tempus' stock price is at or below $48.42, or, if above that floor, the number of Tempus shares equal to $16.25 divided by the Tempus stock price.

Tempus may also elect, any time before the third business day prior to closing, to pay cash for up to 50% of Personalis' outstanding shares at $16.25 per share, with the rest paid in Tempus stock. Personalis said stockholders may therefore not know the final mix of stock and cash, or the exchange ratio, when they vote.

The Personalis board unanimously recommends that stockholders vote "FOR" the merger proposal, "FOR" an advisory proposal on merger-related executive compensation, and "FOR" a proposal to adjourn the meeting if needed to gather more votes.

The deal structure and the shareholder votes

The transaction is structured as two sequential mergers. First, Aviary Development, Inc., a Tempus subsidiary, merges into Personalis, leaving Personalis as a wholly owned Tempus subsidiary. Immediately afterward, Personalis merges into Toucan Development, LLC, another Tempus subsidiary, which survives.

Approval requires the affirmative vote of holders of a majority of Personalis' outstanding common stock. Two large holders have already committed: Merck Sharp & Dohme LLC, which held about 13% of Personalis' voting power as of the record date, signed a voting agreement to support the deal, and Tempus itself, which held about 12%, also agreed to vote in favor.

The filing states that no Tempus stockholder approval is required for the mergers or for the issuance of Tempus shares as consideration, and that Tempus will not call a stockholder meeting on the transaction.

What this means

A DEFM14A is a definitive proxy statement filed with the SEC when a company asks shareholders to vote on a major transaction. "Definitive" means it is the final version that can be mailed to shareholders, as opposed to a preliminary proxy filed earlier for SEC review. It is the document that formally puts a merger to a shareholder vote.

The exchange ratio is the number of acquirer shares a target shareholder receives for each share owned. Here, the formula works out to roughly $16.25 of Tempus stock per Personalis share as long as Tempus trades above $48.42. If Tempus trades below that floor, the ratio is fixed at 0.3356, so the value received would fall below $16.25 with Tempus' price. The $16.25 figure is also the cash price Tempus would pay if it makes the optional cash election.

The filing does not explain why the two companies agreed to merge. It describes the terms, the board's recommendation, the voting agreements and the meeting logistics, but the source provided here does not give the strategic rationale.

If shareholders approve, the next step is closing the merger, subject to the remaining conditions in the agreement. If they do not, the merger cannot be completed under the terms described.